Last reviewed · How we verify

Onabotulinum Toxin A

Walter Reed National Military Medical Center · FDA-approved active Small molecule

Onabotulinum Toxin A is a Botulinum toxin Small molecule drug developed by Walter Reed National Military Medical Center. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: BTX-A, Botox, BOTOX.

Onabotulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Onabotulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinum Toxin A
Also known asBTX-A, Botox, BOTOX
SponsorWalter Reed National Military Medical Center
Drug classBotulinum toxin
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology, Dermatology, Ophthalmology
PhaseFDA-approved

Mechanism of action

The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Onabotulinum Toxin A

What is Onabotulinum Toxin A?

Onabotulinum Toxin A is a Botulinum toxin drug developed by Walter Reed National Military Medical Center, indicated for Cervical dystonia, Blepharospasm, Strabismus.

How does Onabotulinum Toxin A work?

Onabotulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is Onabotulinum Toxin A used for?

Onabotulinum Toxin A is indicated for Cervical dystonia, Blepharospasm, Strabismus, Chronic migraine, Hyperhidrosis.

Who makes Onabotulinum Toxin A?

Onabotulinum Toxin A is developed and marketed by Walter Reed National Military Medical Center (see full Walter Reed National Military Medical Center pipeline at /company/walter-reed-national-military-medical-center).

Is Onabotulinum Toxin A also known as anything else?

Onabotulinum Toxin A is also known as BTX-A, Botox, BOTOX.

What drug class is Onabotulinum Toxin A in?

Onabotulinum Toxin A belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is Onabotulinum Toxin A in?

Onabotulinum Toxin A is FDA-approved (marketed).

What are the side effects of Onabotulinum Toxin A?

Common side effects of Onabotulinum Toxin A include Headache, Neck pain, Injection site pain, Muscle weakness, Eyelid ptosis, Dry mouth.

What does Onabotulinum Toxin A target?

Onabotulinum Toxin A targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Botulinum toxin.

Related